Journal
AUTOIMMUNITY REVIEWS
Volume 15, Issue 11, Pages 1031-1033Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2016.07.028
Keywords
Lupus Anticoagulant; Phospholipids; Russell Viper Venom; Thrombosis; ss2-glycoprotein 1; cardiolipin; syndrome; inhibitor
Categories
Ask authors/readers for more resources
Diagnosis of antiphospholipid syndrome (APS) is essentially based on the detection of circulating antiphospholipid (aPL) antibodies. Progress have been made on the standardization of tests exploring the presence of aPL as guidelines on coagulation and immunological tests were recently published in the literature. Clinical relevance of aPL profile has come from prospective cohort studies in populations with a homogeneous antibody profile supporting the view that triple positivity is a high risk pattern in patients and carriers. In addition to the classic ones, several other tests have been proposed for the diagnosis of APS. The detection of antibodies directed to domain 1 and 4/5 of (beta 2-Glycoprotein I (beta 2GP1) were found to be particularly sound. Several issues remain to be addressed. We do not yet know what is the physiological function of beta 2GP1 and the pathophysiology of thrombosis and pregnancy loss in these patients. Moreover, treatment is poorly defined especially in the case of feared catastrophic APS. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available